Tailoring radiotherapy to the needs of your patient

Tailoring radiotherapy to the needs of your patient

Procedure workflows in radiotherapy

ZEISS Ophthalmology cataract Efficiency without compromise

Immediate treatment precisely where needed

Neuro tumor treatments are one of the most challenging disciplines. Our ZEISS Tumor Workflow helps you to reconsider the standard of care and supports you with most precise, faster and overall more efficient treatment options than today.

ZEISS Ophthalmology cornea refractive Grow your business with one LVC portfolio

Increasing the overall survival for early-stage breast cancer

Intraoperative radiotherapy (IORT) for breast cancer using ZEISS technology enables a precise treatment which can reduce the risk of recurrence, increase the overall survival and reduce side-effects such as pain and cosmesis compared to conventional radiotherapy treatments.1,2,3,4

ZEISS Ophthalmology Connecting your procedure workflow
ZEISS Ophthalmology Connecting your procedure workflow

The benefits of intraoperative radiotherapy (IORT) using ZEISS technology

ZEISS Solution for radiotherapy

IORT enables a targeted, risk-adapted and interdisciplinary treatment of various tumors, such as neuro tumors or breast cancer but also other indications. By using low energy x-rays IORT can be given with a high dose, precisely into the tumor or directly after resection to the tumor bed.

ZEISS Intrabeam 600

ZEISS INTRABEAM 600: Melding two worlds into one benefit.

Combining surgery and radiotherapy, ZEISS INTRABEAM 600 enables an individual IORT treatment ensuring that skin and deeper structures are protected and a shorter duration of the radiation therapy compared to external beam radiation therapy (EBRT). This can also reduce associated side effects and enhances treatment comfort for the patient – a key element in increased quality of life.1

Explore procedure workflow for brain tumor treatment

ZEISS Virtual Experience Showroom

  • 1

    Vaidya, J. S., et al. (2020). Long-term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ, 370, m2836. https://doi.org/10.1136/bmj.m2836

  • 2

    Corica, T., et al. (2018). Cosmetic outcome as rated by patients, doctors, nurses and BCCT. core software assessed over 5 years in a subset of patients in the TARGIT-A Trial. Radiation Oncology (2018) 13:68. https://doi.org/10.1186/s13014-018-0998-x

  • 3

    Keshtgar, M. R., et al. (2013) Objective assessment of cosmetic outcome after targeted intraoperative radiotherapy in breast cancer: results from a randomised controlled trial. Breast Cancer Research and Treatment 140, pages 519–525, doi.org/10.1007/s10549-013-2641-8

  • 4

    Welzel, G., et al. (2013) Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Radiation Oncology Journal 8, 9. doi.org/10.1186/1748-717X-8-9